Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Market Outperform and raises the price target from $35 to $36.
